María-Victoria Mateos: Bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma
We were delighted to speak with María-Victoria Mateos (University of Salamanca, Salamanca, Spain) about the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma.
Disclosures: María-Victoria Mateos discloses the following – Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees from Amgen, Celgene, GlaxoSmithKline, Janssen and Takeda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Nicola Cartridge.
View more multiple myeloma content:
- Dr María-Victoria Mateos (University of Salamanca, Salamanca, Spain) shares her thoughts on the current challenges in CAR-T cell therapy and the strategies being investigated to address them. Watch here on touchHAEMATOLOGY
- Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Watch here
- Dr Joseph Franz and Dr Sagar Lonial discuss the recent ATLAS study (ClinicalTrials.gov Identifier: NCT02659293) and optimal post-ASCT management in patients with multiple myeloma. Read here
